GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Metrics to compare | GRAL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGRALPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.8x | −3.8x | −0.5x | |
PEG Ratio | −0.03 | −0.19 | 0.00 | |
Price/Book | 0.5x | 2.3x | 2.6x | |
Price / LTM Sales | 9.1x | 8.7x | 3.3x | |
Upside (Analyst Target) | 23.0% | 352.5% | 38.7% | |
Fair Value Upside | Unlock | −10.0% | 5.0% | Unlock |